Section 126-BB:1 - Definitions In this chapter:
I. "Board" means the New Hampshire prescription drug affordability board.II. "Brand-name drug" means a prescription drug marketed under a proprietary name or registered trademark name, including a biological product.III. "Generic drug" means a prescription drug, whether identified by its chemical, proprietary, or nonproprietary name, that is not a brand-name drug and is therapeutically equivalent to a brand-name drug in dosage, safety, strength, method of consumption, quality, performance, and intended use. "Generic drug" includes a biosimilar product.IV. "Manufacturer" means a manufacturer of prescription drugs that are distributed in the state. A manufacturer excludes a packager, repackager, labeler, and relabeler unless the packager, repackager, labeler, or relabeler sets the price or controls the price of a prescription drug.V. "Pricing unit" means the smallest available package that can be used to dispense the smallest amount of a prescription drug.VI. "Public payor" means any division of state, county, or municipal government that administers a health plan for its employees or an association of state, county, or municipal employers that administers a health plan for its employees.VII. "Wholesale acquisition cost" means a manufacturer's listed price for sale to a wholesale drug distributor or other entity that purchases a prescription drug directly from the manufacturer, not including any price concessions.Amended by 2022 , 244: 1, eff. 7/1/2022.Added by 2020 , 13: 5, eff. 7/1/2020.